Moscow, Russia- On December 18, 2023, MicroPort^® CardioFlow completed the first implantation of its VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®) in Russia, marking the completion of a highly complex Type 0 bicuspid aortic valve implantation with an extremely horizontally positioned heart via Transcatheter Aortic Valve Implantation (TAVI). Led by Professor Imaev Timur of the Russian National Medical Research Center for Cardiovascular Surgery, with guidance from Chinese experts, the team achieved precise deploy and successful release of the valve without the need for post-dilation. Post-operative echocardiography showed good valve shape and position, with no paravalvular leakage or conduction abnormalities, confirming the success of the procedure.

Shanghai, China-Recently, the second-generation balloon catheter-Alwide Plus Balloon Catheter (hereinafter referred to as "Alwide Plus") self-developed by MicroPort^® CardioFlow Medtech Corporation (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK) was approved for marketing by Saudi Food & Drug Authority.

London, UK - November 19th - November 21st, 2023, evidence-based data from the VitaFlow^® Transcatheter Aortic Valve (VitaFlow^®), developed by MicroPort^® CardioFlow (hereinafter referred to as MicroPort^® CardioFlow, stock code: 02160.HK), were revealed on PCR London Valves, a leading global event on structural heart diseases. The data showed that the long-term and excellent clinical outcomes of VitaFlow^® have reached the international mainstream level, and this is also the first time for the domestically-developed transcatheter aortic valve system to publish 7-year long-term follow-up data in the international authoritative academic arena in the field of interventional treatment of heart valve disease.